Display options
Cite
Tafelski S, Wagner L, Angermair S, et al. Therapeutic drug monitoring for colistin therapy in severe multi-resistant . SAGE Open Med Case Rep. 2017;5:2050313X17711630doi: 10.1177/2050313X17711630.
Tafelski, S., Wagner, L., Angermair, S., Deja, M. (2017). Therapeutic drug monitoring for colistin therapy in severe multi-resistant . SAGE open medical case reports, 52050313X17711630. https://doi.org/10.1177/2050313X17711630
Tafelski, Sascha, et al. "Therapeutic drug monitoring for colistin therapy in severe multi-resistant ." SAGE open medical case reports vol. 5 (2017): 2050313X17711630. doi: https://doi.org/10.1177/2050313X17711630
Tafelski S, Wagner L, Angermair S, Deja M. Therapeutic drug monitoring for colistin therapy in severe multi-resistant . SAGE Open Med Case Rep. 2017 Jun 19;5:2050313X17711630. doi: 10.1177/2050313X17711630. eCollection 2017. PMID: 28680633; PMCID: PMC5480626.
Copy Download .nbib Format: NLM
Share it on

SAGE Open Med Case Rep. 2017 Jun 19;5:2050313X17711630. doi: 10.1177/2050313X17711630. eCollection 2017.

Therapeutic drug monitoring for colistin therapy in severe multi-resistant .

SAGE open medical case reports

Sascha Tafelski, Lukas Wagner, Stefan Angermair, Maria Deja,

Affiliations

  1. Charité Virchow Klinikum and Campus Mitte, Berlin, Germany.
  2. Charité Benjamin Franklin, Berlin, Germany.

PMID: 28680633 PMCID: PMC5480626 DOI: 10.1177/2050313X17711630

Abstract

OBJECTIVES: Intracranial infections due to multidrug- resistant (MDR) gram-negative pathogens are associated with increased morbidity and mortality. As therapeutic options are limited and systemic drug penetration into the infection focus is difficult, intraventricular therapy has been described.

METHODS: We report on a patient with intracranial abscess caused by MDR Acinetobacter baumannii.

RESULTS: He was treated with high doses of intravenous and intraventricular colistin resulting in microbiological clearance and clinical cure. Therapy was controlled by therapeutic drug monitoring (TDM) of serum and liquor colistin levels. About 100 cases with intraventricular or intrathecal colistin are reported in literature but data on TDM are sparse.

CONCLUSIONS: This is one of the first cases providing data on TDM for locally administered high dose colistin therapy for the treatment of intracranial abscess formations. Based on these findings, increasing the intraventricular application interval paralleled with intravenous colistin could possibly be sufficient to achieve appropriate therapeutic drug levels. Further studies are needed to support alternative dosing strategies in similar cases.

Keywords: Acinetobacter baumannii; Colistin; meningitis; therapeutic drug monitoring

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Acta Neurochir (Wien). 2016 Mar;158(3):603-10; discussion 610 - PubMed
  2. Int J Antimicrob Agents. 2013 Jun;41(6):499-508 - PubMed
  3. Antimicrob Agents Chemother. 2010 Sep;54(9):3985-7 - PubMed
  4. N Engl J Med. 2014 Jul 31;371(5):447-56 - PubMed
  5. Ann Trop Paediatr. 2009 Jun;29(2):141-7 - PubMed
  6. Eur J Neurol. 2016 Jan;23(1):68-75 - PubMed
  7. Case Rep Infect Dis. 2016;2016:8794696 - PubMed
  8. Clin Infect Dis. 2004 Nov 1;39(9):1267-84 - PubMed
  9. Int J Clin Exp Med. 2015 Nov 15;8(11):21833-8 - PubMed
  10. J Neurosci Rural Pract. 2016 Jul-Sep;7(3):450-2 - PubMed
  11. Int J Antimicrob Agents. 2013 Oct;42(4):357-60 - PubMed
  12. Int J Antimicrob Agents. 2013 May;41(5):480-3 - PubMed
  13. Clin Microbiol Infect. 2016 Jan;22(1):66-70 - PubMed
  14. Antimicrob Agents Chemother. 2012 Aug;56(8):4416-21 - PubMed
  15. Expert Rev Anti Infect Ther. 2014 Apr;12(4):471-8 - PubMed
  16. Clin Microbiol Infect. 2012 Jan;18(1):30-9 - PubMed
  17. Eur J Clin Pharmacol. 2013 Jul;69(7):1429-36 - PubMed
  18. Antimicrob Agents Chemother. 2013 Apr;57(4):1938-40 - PubMed

Publication Types